Stent thrombosis and major clinical events at 3 years after zotarolimus-eluting or sirolimus-eluting coronary stent implantation: a randomised, multicentre, open-label, controlled trial

@article{Camenzind2012StentTA,
  title={Stent thrombosis and major clinical events at 3 years after zotarolimus-eluting or sirolimus-eluting coronary stent implantation: a randomised, multicentre, open-label, controlled trial},
  author={Edoardo Camenzind and William Wijns and Laura Mauri and Volkhard Kurowski and for the PROTECT Steering Committee and Investigators},
  journal={The Lancet},
  year={2012},
  volume={380},
  pages={1396-1405}
}
BACKGROUND We sought to compare the long-term safety of two devices with different antiproliferative properties: the Endeavor zotarolimus-eluting stent (E-ZES; Medtronic, Inc) and the Cypher sirolimus-eluting stent (C-SES; Cordis, Johnson & Johnson) in a broad group of patients and lesions. METHODS Between May 21, 2007 and Dec 22, 2008, we recruited 8791 patients from 36 recruiting countries to participate in this open-label, multicentre, randomised, superiority trial. Eligible patients were… CONTINUE READING
Related Discussions
This paper has been referenced on Twitter 8 times. VIEW TWEETS

Citations

Publications citing this paper.
Showing 1-10 of 59 extracted citations

External Validation of the DAPT Score in a Nationwide Population.

Journal of the American College of Cardiology • 2018
View 1 Excerpt

References

Publications referenced by this paper.
Showing 1-10 of 37 references

Myocardial infarction adjudication in contemporary all-comer stent trials: balancing sensitivity and specificity. Addendum to the historical MI definitions used in stent studies.

EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology • 2010

Similar Papers

Loading similar papers…